Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29524321 | 0.81 | PRSS1 (0.48) | MAPTMEN1KMT2ANPC1MKNK1 | |
| SCHEMBL8842473 | 0.81 | PRSS1 (0.48) | MAPTMEN1KMT2ANPC1MKNK1 | |
| SCHEMBL3604237 | 0.76 | KMT2A (0.33) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL29014990 | 0.72 | NPC1 (0.60) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL30450715 | 0.72 | NPC1 (0.60) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8842460 | 0.71 | MEN1 (0.50) | MAPTMEN1KMT2ANPC1CCNT1 | |
| SCHEMBL30450701 | 0.69 | NPC1 (0.52) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL29015025 | 0.69 | NPC1 (0.52) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL3658282 | 0.69 | MKNK1 (0.54) | MKNK1MKNK2CCNT1CDK9ALDH1A1 | |
| SCHEMBL8842604 | 0.69 | CYP1A1 (0.49) | MAPTMEN1KMT2ANPC1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1545544-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| US-5686456-A | DIARYLPYRIMIDINES | THE UNIVERSITY OF NORTH CAROLINA (US) | 1997-11-11 | — | — | US | claimed |
| US-5622955-A | ADMINISTERING 2,4-BIS-/4-GUANYLPHENYL/-PYRIMIDINE OR DERIVATIVES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-04-22 | — | — | US | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2121700-B1 | SUBSTITUTED TETRAHYDROQUINOLINES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-5686456-A | DIARYLPYRIMIDINES | THE UNIVERSITY OF NORTH CAROLINA (US) | 1997-11-11 | — | — | US | disclosed |
| US-5627184-A | BACTERICIDES OF PYRIMIDINE DERIVATIVES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-05-06 | — | — | US | disclosed |
| US-5622955-A | ADMINISTERING 2,4-BIS-/4-GUANYLPHENYL/-PYRIMIDINE OR DERIVATIVES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-04-22 | — | — | US | disclosed |
| US-5606058-A | HAVING REDUCED SIDE EFFECTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-25 | — | — | US | disclosed |
| US-5521189-A | PYRIMIDINE COMPOUNDS AS ANTIPROTOZOA AGENTS | THE UNIVERSITY OF NC AT CH (US) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | MAPT 4349/4885MEN1 37/4885KMT2A 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.